SCHEMBL6927666

SCHEMBL6927666

O=S(=O)(Nc1ccc(F)cc1F)c1ccc2[nH]c(-c3ccccn3)nc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CBFB Q13951 6/20 0.54
METAP1 P53582 4/20 0.54
METAP2 P50579 3/20 0.54
MAPT P10636 5/20 0.51
TP53 P04637 1/20 0.51
LMNA P02545 4/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
KDM4E B2RXH2 3/20 0.46
PKM P14618 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KMT2A Q03164 2/20 0.46
HPGD P15428 2/20 0.45
MTOR P42345 1/20 0.45
GLO1 Q04760 2/20 0.44
SLC40A1 Q9NP59 1/20 0.43
HSP90AA1 P07900 1/20 0.43
HSP90AB1 P08238 1/20 0.43
GCK P35557 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6926724 0.91 CBFB (0.55) CBFBMETAP1METAP2MAPTTP53
SCHEMBL6925826 0.87 MAPT (0.49) MAPTTP53LMNAKDM4EKMT2A
SCHEMBL6926524 0.85 MAPT (0.68) MAPTTP53LMNAKDM4ESMN1; SMN2
SCHEMBL11370367 0.85 MAPT (0.48) MAPTTP53LMNAKDM4ESMN1; SMN2
SCHEMBL6925468 0.83 CBFB (0.53) CBFBMETAP1METAP2MAPTLMNA
SCHEMBL6926224 0.83 MAPT (0.46) MAPTTP53LMNAGLO1
SCHEMBL6927054 0.80 TSHR (0.48) CBFBMAPTTP53LMNAKDM4E
SCHEMBL6926929 0.80 METAP2 (0.51) CBFBMETAP2MAPTTP53LMNA
SCHEMBL6915949 0.80 CBFB (0.54) CBFBMETAP1METAP2MAPTLMNA
SCHEMBL30692552 0.79 CBFB (0.78) CBFBMETAP1METAP2MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120184556-A1 SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2012-07-19 US disclosed
US-20120184556-A1 SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2012-07-19 US disclosed
WO-2011011722-A1 SUBSTITUTED BENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS VANDERBILT UNIVERSITY (US) 2011-01-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184556-A1 SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS GRM4, GRIK4, GRIA4 CBFB 4529/4885METAP1 1137/4885METAP2 1092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.